What Is Lp(a) (Lipoprotein a)? Normal vs Optimal Range Explained

Lp(a) is structurally unique—it is an LDL-like particle with an additional apolipoprotein(a) protein wrapped around it, giving it both the atherogenic properties of LDL and the prothrombotic properties of a plasminogen mimic that interferes with the body's clot-dissolving machinery. The CTD maps over 260 compound interactions affecting Lp(a) metabolism and the coagulation pathways it disrupts. Unlike every other lipoprotein, Lp(a) levels are approximately 90% genetically determined by the LPA gene and are minimally responsive to diet, exercise, or most medications. Above 75 nmol/L (or 30 mg/dL), Lp(a) confers independent cardiovascular risk that compounds with every other risk factor present. Approximately one in five people globally carries elevated Lp(a), yet it remains one of the least commonly tested cardiovascular biomarkers despite its prevalence and clinical significance. Checking it once in a lifetime is sufficient since the level does not meaningfully change.

The cardiovascular risk from elevated Lp(a) operates through two parallel mechanisms that make it particularly dangerous. PubMed indexes over 16,000 publications on Lp(a), with Mendelian randomization analyses providing the strongest possible genetic evidence that elevated Lp(a) is a causal—not merely correlated—driver of coronary artery disease, aortic valve stenosis, and stroke. The LDL-like component delivers cholesterol into artery walls exactly like standard LDL particles, contributing to plaque formation. The apolipoprotein(a) component competitively inhibits plasminogen activation on the endothelial surface, impairing the body's ability to dissolve clots that form on plaque surfaces. This dual mechanism means elevated Lp(a) simultaneously builds more plaque and makes that plaque more likely to trigger a thrombotic event when it ruptures.

The therapeutic landscape for elevated Lp(a) is evolving rapidly. FAERS data document Lp(a) changes across limited medication entries because most existing drugs do not significantly lower it. Statins—the cornerstone of cardiovascular prevention—may paradoxically increase Lp(a) by 10–20 percent, though this is generally outweighed by their LDL and ApoB reductions. Niacin (vitamin B3) can lower Lp(a) by 20–30 percent, but cardiovascular outcome benefit from niacin specifically for Lp(a) is unproven. PCSK9 inhibitors reduce Lp(a) by approximately 20–30 percent as a secondary effect. The most promising development is antisense oligonucleotide therapy (pelacarsen) targeting hepatic Lp(a) production, which reduces levels by over 80 percent in clinical trials. For individuals with elevated Lp(a) today, the clinical strategy focuses on aggressively managing every other modifiable risk factor—ApoB, blood pressure, hs-CRP, and metabolic health—to offset the inherited risk that cannot yet be pharmacologically eliminated.